CELLULAR CANCER VACCINES--GPI PROTEIN TRANSFER
细胞癌疫苗--GPI蛋白转移
基本信息
- 批准号:2372175
- 负责人:
- 金额:$ 23.77万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-09-01 至 2002-07-31
- 项目状态:已结题
- 来源:
- 关键词:MHC class II antigen antigen presenting cell biotechnology cellular immunity cytotoxic T lymphocyte enzyme linked immunosorbent assay glycosylphosphatidylinositols human tissue immunoconjugates immunomodulators laboratory mouse neoplasm /cancer immunotherapy neoplasm /cancer vaccine oncoproteins protein engineering transfection tumor antigens vaccine development
项目摘要
This proposal deals with practical applications of glycosyl-
phoshatidylinositol (GPI) protein tranfer, with the objectives geares
towards clinical translation down the road. The overall goal is to
develop immunotherapies for cancer which which use eith engineered tumor
cells themselves (painted with costimulator-GPI proteins, such as
B7-1-GPI and B7-2-GPI) or antigenically engineered professional
antigen-presenting cells (APCs)(painted with MHC-GPI. Tumor peptide
antigen complexes) as cellular vaccines to elicit systemic anti-tumor
responses. Accomplishments to data have contributed towards the use of
protein transfer as a tool for producing each of these kinds of cellular
vaccines. Significantly, protein transfer, unlike gene transfer, is
reality applicable to primary tumor cells and professional APCs that are
difficult to transfect and facilitaes the simultanceous expression of
multiple proteins at the cell surface. The present proposal consists of
five specific amis which are intended to serve as a platform for cancer
therapeutics development and later clinical trials with adjuvant cancer
vaccines: (1) ex vivo and in vivo studies with B7-1GPI and B7-2-GPI
proteins will be completed; (2) The usefulness of other (non-B7)
costomulator.GPIs for immunogenic tumore cell engineering, along with
other potentially agents, will be evaluated; (3) The feasibilty of
generating immunogenic tumor cells in the situ within tumor beds will be
determined; (4) Functional studies with HLA-A2.1'GPIs bearing
well-defined tumor peptide antigens will be conducted; and (5)
Additional developmental work on GPI protein transfer per se will be
performed.
本建议涉及糖基的实际应用,
磷脂酰肌醇(GPI)蛋白转移,目的是
临床转化的可能性 总体目标是
开发癌症的免疫疗法,
细胞本身(涂有共刺激因子GPI蛋白,如
B7-1-GPI和B7-2-GPI)或抗原工程专业人员
抗原呈递细胞(APC)(涂有MHC-GPI。肿瘤肽
抗原复合物)作为细胞疫苗以引发全身性抗肿瘤
应答 数据方面的成就有助于使用
蛋白质转移作为一种工具,
疫苗。 值得注意的是,蛋白质转移与基因转移不同,
现实适用于原发性肿瘤细胞和专业APC,
很难理解,也很容易同时表达
细胞表面的多种蛋白质。本提案包括:
五种特定的AMIs,旨在作为癌症的平台,
辅助癌症的治疗学开发和后期临床试验
疫苗:(1)B7- 1 GPI和B7-2-GPI的离体和体内研究
蛋白质将完成;(2)其他(非B7)的有用性
用于免疫原性肿瘤细胞工程的GPIs,沿着
其他潜在的代理人,将进行评估;(3)的可行性,
在肿瘤床内原位产生免疫原性肿瘤细胞将
(4)HLA-A2. 1 'GPIs基因的功能研究
将进行明确定义的肿瘤肽抗原;和(5)
关于GPI蛋白转移本身的其他开发工作将在
执行。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mark L Tykocinski其他文献
Mark L Tykocinski的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mark L Tykocinski', 18)}}的其他基金
Placental Protein 14 as a Lectin-Like Immunomodulator
胎盘蛋白 14 作为凝集素样免疫调节剂
- 批准号:
6581043 - 财政年份:2002
- 资助金额:
$ 23.77万 - 项目类别:
Placental Protein 14 as a Lectin-Like Immunomodulator
胎盘蛋白 14 作为凝集素样免疫调节剂
- 批准号:
6690355 - 财政年份:2002
- 资助金额:
$ 23.77万 - 项目类别:
Placental Protein 14 as a Lectin-Like Immunomodulator
胎盘蛋白 14 作为凝集素样免疫调节剂
- 批准号:
6826845 - 财政年份:2002
- 资助金额:
$ 23.77万 - 项目类别:
CELLULAR CANCER VACCINES--GPI PROTEIN TRANSFER
细胞癌疫苗--GPI蛋白转移
- 批准号:
2896054 - 财政年份:1997
- 资助金额:
$ 23.77万 - 项目类别:
CELLULAR CANCER VACCINES--GPI PROTEIN TRANSFER
细胞癌疫苗--GPI蛋白转移
- 批准号:
6376458 - 财政年份:1997
- 资助金额:
$ 23.77万 - 项目类别:
相似海外基金
Antigen-Presenting Cell Control of CD8+ T Cell Exhaustion in Cancer
癌症中 CD8 T 细胞耗竭的抗原呈递细胞控制
- 批准号:
10659843 - 财政年份:2023
- 资助金额:
$ 23.77万 - 项目类别:
Regulation of Antitumor T-cell repertoire responses by antigen presenting cell subsets
抗原呈递细胞亚群调节抗肿瘤 T 细胞库反应
- 批准号:
23H02706 - 财政年份:2023
- 资助金额:
$ 23.77万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of a novel artificial antigen presenting cell to study human CD8 T cell biology
开发新型人工抗原呈递细胞来研究人类 CD8 T 细胞生物学
- 批准号:
574458-2022 - 财政年份:2022
- 资助金额:
$ 23.77万 - 项目类别:
University Undergraduate Student Research Awards
Development of a novel artificial antigen presenting cell to study human CD8 T cell biology
开发新型人工抗原呈递细胞来研究人类 CD8 T 细胞生物学
- 批准号:
564338-2021 - 财政年份:2021
- 资助金额:
$ 23.77万 - 项目类别:
University Undergraduate Student Research Awards
Molecular mechanisms on antigen presenting cell function and generation
抗原呈递细胞功能和生成的分子机制
- 批准号:
20H03505 - 财政年份:2020
- 资助金额:
$ 23.77万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Preserving T cell / antigen presenting cell interactions via shared L-arginine
通过共享 L-精氨酸保留 T 细胞/抗原呈递细胞相互作用
- 批准号:
10240447 - 财政年份:2020
- 资助金额:
$ 23.77万 - 项目类别:
Lung Megakaryocytes Are A Novel Professional Antigen Presenting Cell
肺巨核细胞是一种新型专业抗原呈递细胞
- 批准号:
9759173 - 财政年份:2019
- 资助金额:
$ 23.77万 - 项目类别:
Antigen presenting cell mediated regulation of intestinal inflammation
抗原呈递细胞介导的肠道炎症调节
- 批准号:
18K15128 - 财政年份:2018
- 资助金额:
$ 23.77万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Epithelial cell-antigen presenting cell crosstalk in the maintenance of immune homeostasis in the lung
上皮细胞-抗原呈递细胞串扰维持肺免疫稳态
- 批准号:
1640539 - 财政年份:2015
- 资助金额:
$ 23.77万 - 项目类别:
Studentship
The role of GCN2-kinase in antigen presenting cell function and tolerance to self
GCN2激酶在抗原呈递细胞功能和自身耐受性中的作用
- 批准号:
8662697 - 财政年份:2013
- 资助金额:
$ 23.77万 - 项目类别: